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upregulation of mTOR
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Background: The t(6;9)(p23;q34) chromosomal translocation is found in 1% of acute myeloid leukemia and
encodes the fusion protein DEK-NUP214 (formerly DEK-CAN) with largely uncharacterized functions.
Methods: We expressed DEK-NUP214 in the myeloid cell lines U937 and PL-21 and studied the effects on
cellular functions.
Results: In this study, we demonstrate that expression of DEK-NUP214 increases cellular proliferation. Western blot
analysis revealed elevated levels of one of the key proteins regulating proliferation, the mechanistic target of
rapamycin, mTOR. This conferred increased mTORC1 but not mTORC2 activity, as determined by the
phosphorylation of their substrates, p70 S6 kinase and Akt. The functional importance of the mTOR upregulation
was determined by assaying the downstream cellular processes; protein synthesis and glucose metabolism. A
global translation assay revealed a substantial increase in the translation rate and a metabolic assay detected a shift
from glycolysis to oxidative phosphorylation, as determined by a reduction in lactate production without a
concomitant decrease in glucose consumption. Both these effects are in concordance with increased mTORC1
activity. Treatment with the mTORC1 inhibitor everolimus (RAD001) selectively reversed the DEK-NUP214-induced
proliferation, demonstrating that the effect is mTOR-dependent.
Conclusions: Our study shows that the DEK-NUP214 fusion gene increases proliferation by upregulation of
mTOR, suggesting that patients with leukemias carrying DEK-NUP214 may benefit from treatment with
mTOR inhibitors.
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Acute myeloid leukemia (AML) is characterized by the
dysregulated proliferation and impaired differentiation of
myeloid precursor cells. Many of these leukemias harbor
genetic translocations, which determine both the molecu-
lar mechanistics and the prognosis of the disease [1]. The
t(6;9)(p23;q34) chromosomal translocation is found in 1%
of AML, where it is associated with young age and poor
prognosis [2]. The translocation occurs between specific
introns in the gene DEK on chromosome 6 and the gene
NUP214 on chromosome 9, creating the fusion gene* Correspondence: carl.sanden@med.lu.se
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reproduction in any medium, provided the orDEK-NUP214 (formerly DEK-CAN). The original reading
frames are preserved, yielding an invariable fusion protein
comprising almost the entire chromatin remodeling
protein DEK and the carboxy-terminal two thirds of the
nucleoporin NUP214 [3].
Despite extensive characterization of many other fusion
genes, the role of DEK-NUP214 is still poorly understood.
We have previously shown that DEK-NUP214 promotes
the activating phosphorylation of the eukaryotic translation
initiation factor 4E (eIF4E) on Ser209 and increases the
protein synthesis of myeloid cells [4]. However, the cause
as well as the cellular effects thereof remain to be explored.
Recently, DEK-NUP214 has been shown to induce
leukemia in a murine model, but only from long-term
repopulating stem cells and with long latency, emphasizingl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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of leukemias with the DEK-NUP214 fusion gene is the
concomitant internal tandem duplication (ITD) in the
tyrosine kinase FLT3. The FLT3-ITD genotype is more
than three times as common in leukemias with t(6;9)
(p23;q34) as in other AML [2,6]. This suggests a classic
oncogenic cooperation between a pro-proliferative FLT3-
ITD and a differentiation-blocking DEK-NUP214. How-
ever, recent studies have identified a role for FLT3-ITD
also in inhibition of myeloid differentiation [7]. And
contrary to many fusion proteins observed in AML,
DEK-NUP214 does not seem to inhibit differentiation,
at least not when expressed in the monocytic cell line
U937 [8]. This raises the possibility of a role for DEK-
NUP214 in proliferation.
The mechanistic target of rapamycin (mTOR) is a
central node in the regulation of both proliferation and
translation [9]. The mTOR protein is found in two com-
plexes. Activated by growth factor signaling, the mTOR
complex 2 (mTORC2) phosphorylates Akt at Thr450 and
Ser473, in turn activating mTOR complex 1 (mTORC1)
[10]. mTORC1 initiates translation by phosphorylation
of its downstream targets, such as the p70 S6 kinase
[11]. Although mTORC1 regulates the translation of most
mRNAs, some transcripts are particularly sensitive. These
include many oncogenes such as c-myc and cyclin D1.
Activation of the mTORC1 pathway thus promotes cellular
growth and proliferation [12,13].
In addition to its role in translation, mTORC1 also
affects cellular metabolism by promoting the more energy-
efficient oxidative phosphorylation over glycolysis. This role
is independent of the translational regulation machinery
and rather seems to involve phosphorylation of mitochon-
drial enzymes [14,15]. Due to its multiple roles in carcino-
genesis and its common overactivation in cancer, mTOR
has become an attractive target for cancer therapy and
there are currently several inhibitors in clinical trials [16].
Recently, the FDA approved the highly specific mTORC1
inhibitors everolimus (RAD001) and temserolimus (CCI-
779) for the treatment of advanced renal cell carcinoma
and everolimus is currently in clinical trial for acute myeloid
leukemia [17-19].
In this study, we show that overexpression of DEK-
NUP214 in the myeloid cell line U937 leads to increased
levels of mTOR and activation of the mTOR target
p70S6K. This translates into higher protein synthesis
and a metabolic shift from glycolysis to oxidative phosphor-
ylation. Accordingly, cells expressing DEK-NUP214 prolif-
erate faster than their normal counterparts. Treatment with
the mTORC1 inhibitor everolimus selectively reverses
the DEK-NUP214-induced proliferation, suggesting that
the effect is mTOR-dependent and that patients with
t(6;9)(p23;q34) may be suitable for treatment with mTOR
inhibitors.Methods
Cell culture
The cell lines U937 and PL-21 (ATCC, Manassas, VA,
USA) and stable clones derived thereof were cultured
in RPMI 1640 medium (Life Technologies, Carlsbad,
CA, USA) supplemented with 10% fetal bovine serum
(Life Technologies). Stable clones expressing either the
DEK-NUP214 fusion gene [4], DEK-NUP214 deletion
mutants [4] or the corresponding empty pcDNA3 vector,
were generated by electroporation followed by incubation
for 48 h and subsequent seeding of 10 000 cells per well in
100 μl medium. After two weeks of selection by culture in
growth medium supplemented with 0.5 mg/ml geneticin
(Life Technologies), clones were selected and expanded.
Proliferation experiments
For proliferation experiments, cells were seeded in fresh
culture medium at a density of 0.5 × 106 cells/ml and when
indicated treated with daily additions of the mTORC1
inhibitor everolimus (Sigma-Aldrich, St. Louis, MO,
USA). Cell counting was performed with the Countess
Automated Cell Counter (Life Technologies) and viability
was determined on the basis of trypan blue dye exclusion
(Life Technologies).
Protein expression
Protein expression was analyzed by western blot one day
after seeding, as described above. Cells were washed in
PBS (PAA Laboratories, Pasching, Austria), resuspended
and frozen in sample buffer containing 0.1 M Tris–HCl
pH 6.8, 0.2 M β-mercaptoethanol, 14% glycerol (v/v), 3%
SDS (w/v), 0.01% bromophenol blue (w/v), Complete
protease inhibitor cocktail (Roche Diagnostics GmbH,
Mannheim, Germany) and PhosStop protease inhibitor
cocktail (Roche Diagnostics GmbH). Samples were soni-
cated in a UP50H ultrasonic homogenizer (Dr. Hielscher
GmbH, Teltow, Germany), boiled for 5 minutes and
centrifuged at 14 000 × g for 5 minutes. Lysates corre-
sponding to 500 000 cells were run on tris-glycine gels
(Life Technologies) and transferred by an SV20-SDB
semi-dry blotter (Sigma-Aldrich) to Hybond ECL mem-
brane (GE Healthcare, Uppsala, Sweden). Membranes were
blocked with 5% bovine serum albumin (Sigma-Aldrich)
and incubated with one of the following antibodies accor-
ding to the manufacturers’ recommendations: anti-α-tubulin
(Sigma-Aldrich), anti-GAPDH (Santa Cruz Biotechnology,
Santa Cruz, CA, USA), anti-phospho-mTOR-Ser2448, anti-
mTOR, anti-phospho-Akt-Ser473, anti-phospho-Akt-Thr308
or anti-phospho-p70-S6K-Thr389 (Cell Signaling Technol-
ogy, Danvers, MA, USA). HRP-conjugated anti-mouse or
anti-rabbit were used as secondary antibodies (Bio-Rad
Laboratories, Hercules, CA, USA) and detected with the
EZ-ECL kit (Biological Industries, Kibbutz Beit Haemek,
Israel). Quantification was performed using the Molecular
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4.2.2 software (Bio-Rad Laboratories).
Gene expression analysis
Gene expression was determined by quantitative real-time
PCR. RNA was extracted using the RNeasy Mini Kit
(Qiagen GmbH, Hilden, Germany) and reverse transcrip-
tion was performed with the High Capacity cDNA Reverse
Transcription Kit (Life Technologies). Expression levels
were assayed with the TaqMan Gene Expression Assay and
primer-probe pairs for the detection of glyceraldehyde-3-
phosphate dehydrogenase (GAPDH; Hs99999905_m1), me-
chanistic target of rapamycin (mTOR; Hs00234522_m1)
or DEK-NUP214 (custom made) (Life Technologies). The
amplification reaction was performed using the StepOne
Plus Real-Time PCR System (Life Technologies). The
expression of DEK-NUP214 and mTOR was calculated
relative to the expression of GAPDH using the compara-
tive CT method, as previously described [20]. cDNA from
a patient with the t(6;9)(p23;q34) chromosomal transloca-
tion was kindly provided by professor Bertil Johansson at
the Department of Clinical Genetics, Lund University.
Global translation assay
The translation rates of the stable clones were assessed
by radioactive labeling of newly synthesized proteins.
Cells were seeded in fresh culture medium at a density of
0.5 × 106 cells/ml. At indicated time points, EXPRESS35S
Protein Labeling Mix containing radioactively labeled
methionine and cysteine (PerkinElmer, Waltham, MA,
USA), was added to cell cultures to a final concentration
of 50 μCi/ml. After incubation for 2 h, 100 000 viable cells
of each clone were sorted by a FACSAria cell sorter (BD
Bioscience, San José, CA, USA), washed in PBS and lysed
in radioimmunoprecipitation buffer (30 nM HEPES,
pH 7.3, 1% Triton-X (v/v), 1% sodium deoxycholate (w/v),
0.1% SDS (w/v), 0.15 M NaCl) containing the Complete
Protease Inhibitor Cocktail (Roche Diagnostics GmbH,
Mannheim, Germany). Proteins were precipitated by addi-
tion of trichloroacetic acid to a final concentration of 9%.
The precipitate was washed twice in acetone, suspended
in 50 μl 0.1 M Tris–HCl, pH 8.6, and added to 5 ml of
scintillation fluid (Beckman Coulter, Fullerton, CA, USA).
The radioactivity of the samples was measured by a Wallac
Guardian 1414 liquid scintillation counter (PerkinElmer).
Values were corrected for background by subtracting
the values from samples incubated with the EXPRESS35S
Protein Labeling Mix on ice.
Metabolic assays
Cells were seeded in fresh culture medium at a density
of 0.5 × 106 cells/ml. At indicated time points, cell sus-
pension was taken out and centrifuged at 145 × g for
5 minutes. Supernatant was collected and stored at −80°Cto prevent degradation of lactate. The glucose concentra-
tion was measured by applying 10 μl of supernatant to the
Glucose Assay Kit II (BioVision, Mountain View, CA,
USA). After dilution of the supernatant 1:50 in lactate
assay buffer, the lactate concentration was determined
by applying 10 μl to the Lactate Assay Kit II (BioVision).
Absorbance was measured at 450 nm with a Labsystems
Multiskan Plus Plate Reader (Thermo Fisher Scientific,
Waltham, MA, USA).
Statistical analysis
Statistical testing was performed using the two-tailed t
test, where the averages of the three DEK-NUP214 clones
from each experiment were tested against the averages of
the three control clones from the same experiments. Stars
represent conventional significance levels; single stars
indicate p < 0.05, double stars indicate p < 0.01 and triple
stars indicate p < 0.001.
Results
Stable expression of DEK-NUP214 in myeloid cell lines
To investigate the influence of DEK-NUP214 on cellular
functions, we expressed the fusion gene in the myeloid
cell lines U937 and PL-21 and generated stable clones. Ex-
pression of DEK-NUP214 was verified by real-time PCR
(Figure 1A-B). To ensure that the overexpression was in
the same range as endogenously expressed DEK-NUP214,
we quantified the expression of DEK-NUP214 in a sample
from a patient with the t(6;9)(p23;q34) (Figure 1C). The
expression levels in the cell lines were on average 11% of
that in the patient sample and all clones expressed less
DEK-NUP214 than the patient sample, thus reducing the
risk of overexpression artifacts. Protein expression from
the DEK-NUP214 vector was verified by in vitro transla-
tion (data not shown). As previously reported, the fusion
protein does not allow detection by western blot, using
antibodies against either DEK or NUP214 [5]. However,
the verified expression of DEK-NUP214 mRNA by real-
time PCR together with the expression of the geneticin
resistance protein from the same vector during clonal
selection supports that the fusion protein is expressed
in the stable clones.
DEK-NUP214 stimulates the proliferation of U937 and PL-21
To evaluate the leukemia-associated properties of DEK-
NUP214, we first studied its effect on proliferation. Stable
clones constitutively expressing either DEK-NUP214 or
the empty vector were seeded in fresh culture medium
and followed for four days with regard to cell number and
viability. The results show that both U937 and PL-21 cells
expressing DEK-NUP214 expand faster than the respect-
ive control cells (Figure 2A and B). Since the viability did
not differ between the DEK-NUP214 and the control


































































































































































































Figure 1 Expression of the DEK-NUP214 fusion gene. Expression of DEK-NUP214 mRNA by quantitative real-time PCR in the generated stable
clones of (A) U937 and (B) PL-21, as well as (C) a patient sample expressing the fusion gene. Values were calculated relative to the expression of
the endogenous control, which did not differ between the clones. N.d. denotes not detected.









































































































E U937 deletion mutants
DEK-NUP214(813-917)
Δ(
Figure 2 DEK-NUP214 promotes proliferation. Proliferation of (A) U937 and (B) PL-21 cells. Viability of the (C) U937 and (D) PL-21 cell
cultures, as determined by trypan blue dye exclusion. (E) Proliferation of U937 cells expressing deletion mutants of DEK-NUP214. Mean values
were calculated from three independent experiments, containing all clones. Error bars represent S.E.M.
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of increased proliferation. As the DEK-NUP214 and
control cells did not differ in cell cycle distribution (data
not shown), the increased proliferation can be attributed
to a symmetrical decrease of the major cell cycle phases
rather than the shortening of one particular phase. To
determine whether the proliferative effect of DEK-NUP214
is dependent on the entire fusion gene, we performed
the proliferation experiment with previously established
deletion mutants of DEK-NUP214 in U937 cells [4]. To
assess the contribution of the NUP214 part of the fusion,
we used two constructs containing DEK fused with only
either the N-terminal dimerization domain of NUP214,
DEK-NUP214(813–917), or the C-terminal CRM1-binding
domain of NUP214, DEK-NUP214(Δ1-1904). Both of these
constructs failed to reproduce the proliferative effect of the
complete fusion (Figure 2E), demonstrating the importance
of NUP214 for the proliferative effect of the fusion gene.
However, overexpression of NUP214 alone has been
shown to induce growth arrest and apoptosis in U937
cells [8], demonstrating that also the DEK part of the
fusion is essential for the proliferative effect of the
DEK-NUP214 fusion gene.
DEK-NUP214 promotes mTOR signaling
Cellular proliferation is regulated by a wide range of sig-
naling pathways. But the effect on proliferation seen here
and the effect on protein synthesis previously observed
[4], suggested that DEK-NUP214 may act on the major
regulator of translation, the mechanistic target of rapamy-
cin, mTOR [21]. Analysis of the mTOR pathway revealed
that cells expressing DEK-NUP214 have higher levels of
both total mTOR protein and mTOR protein phosphory-
lated at Ser2448 (Figure 3A-C). To determine the impact of
the increased mTOR levels on the activity of the two
mTOR complexes, we analyzed the phosphorylation status
of their downstream targets. The p70 S6 kinase is a
substrate for mTORC1, activated by phosphorylation
by mTOR at Thr389 [22]. Concurrent with mTORC1
activation, we observed an increase in the level of phos-
phorylated p70S6K protein (Figure 3A and B). However,
the mTORC2-mediated phosphorylation of Akt at Ser473
was not affected by the expression of DEK-NUP214
(Figure 3A), suggesting that the increased levels of mTOR
in this case primarily leads to increased mTORC1 activity.
To characterize the mTOR increase, we analyzed the
transcription of the mTOR gene by real-time PCR. This
was unaffected by DEK-NUP214 (Figure 3C), demonstrat-
ing that the increase in mTOR expression occurs on the
post-transcriptional level. We proceeded to examine the
upstream regulators of mTORC1. However, these did not
display altered activation as determined by western blot
against phosphorylated AMPK and GSK3 as well as the
two activating phosphorylations of Akt at Thr308 andSer473 (Figure 3A). The increased phosphorylation of Akt
at Thr308 in the second DEK-NUP214 clone was not seen
in the other DEK-NUP214 clones and was thus attributed
to mechanisms other than the expression of the fusion
protein. In conclusion, our protein expression data
suggests that expression of the DEK-NUP214 fusion
gene leads to higher protein levels of mTOR and increased
signaling through the mTORC1 pathway.
DEK-NUP214 increases protein synthesis
To determine the functional importance of the increased
mTOR signaling, we proceeded to study protein transla-
tion. We performed a global translation assay where the
incorporation of radioactively labeled amino acids into
newly synthesized proteins reflects the rate of translation.
The results show that one day after seeding in fresh culture
medium, U937 cells expressing DEK-NUP214 and control
cells both display high translation rates (Figure 4). However,
three days after seeding, the translation rates have declined
from their maxima and the effect of DEK-NUP214 be-
comes clear. The cells expressing DEK-NUP214 then
had a 68% higher protein synthesis than the control cells
(Figure 4). This demonstrates that DEK-NUP214 sustains
a higher translation rate, in concordance with increased
pro-translational signaling.
DEK-NUP214 induces a metabolic shift
In addition to its role in protein translation, mTOR also
regulates glucose metabolism. In the balance between
aerobic and anaerobic catabolism, mTORC1 promotes
the more energy-efficient oxidative phosphorylation over
glycolysis [15]. We therefore studied the metabolic prop-
erties of the cells by measuring the levels of lactate and
glucose in the cell supernatant after three days of culture.
The U937 cultures expressing DEK-NUP214 produced
15% less lactate, the by-product of glycolysis (Figure 5).
However, the glucose consumption in these cultures was
not proportionally reduced (Figure 5). Thus, this was not
due to an overall reduction in glucose metabolism. Rather,
it suggests a shift in the balance from glycolysis to oxida-
tive phosphorylation, consistent with increased mTORC1
signaling.
The proliferative effect of DEK-NUP214 is dependent
on mTOR
Given the emergence of mTOR inhibitors with clinical
potential, we proceeded to determine the importance
of the upregulated mTOR for the proliferative effect of
DEK-NUP214. Treatment of the U937 cells with the
mTORC1 inhibitor everolimus strikingly ablated the
proliferation increase by DEK-NUP214. When treated
with daily doses of everolimus, the proliferation of cells
expressing DEK-NUP214 was reduced to the level of






















































































































Figure 3 DEK-NUP214 increases the expression of mTOR. A. Phosphorylated and total protein levels for components of the mTOR signaling
pathway in U937 cells one day after seeding, showing increased levels of mTOR and activation of the mTORC1 substrate p70S6K without
activation of the mTORC2 substrate Akt. α-tubulin is used as an equal loading control. Images show one representative experiment out of three.
B. Protein abundance levels of cells expressing DEK-NUP214, relative to control cells. The mean of three experiments, error bars represent S.E.M.
C. Expression of the mTOR gene in DEK-NUP214 cells relative to control cells. The mean of three experiments, error bars represent S.E.M.
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rather than pro-apoptotic, as the viability was consistently
above 90%, similar between DEK-NUP214 and control
cells, and not reduced by the treatment (data not shown).





















Figure 4 DEK-NUP214 promotes translation. Global protein synthesis
as assayed by the incorporation of radioactively labeled amino acids into
newly synthesized protein in U937 cells. All values are normalized to the
level of the control cells one day after seeding. Bars represent the mean
values of three experiments. Error bars represent S.E.M.DEK-NUP214 and control cells, proving its efficacy also
against leukemia cells not expressing this fusion protein
(data not shown). The potency of the mTORC1 inhibitor
was determined by western blot, where treatment with






















Figure 5 DEK-NUP214 alters the balance between glycolysis and
oxidative phosphorylation. Relative concentrations of accumulated
lactate and remaining glucose in cell supernatant three days after
seeding, showing decreased glycolysis but sustained glucose
consumption, indicating increased oxidative phosphorylation in U937
cells expressing DEK-NUP214. Bars represent mean values from three




























Figure 6 The proliferative effect of DEK-NUP214 depends on mTOR. A. Proliferation as determined by U937 cell density three days after
seeding and with daily additions of the mTORC1 inhibitor everolimus. Viability was unaffected by the treatment. Bars represent mean values from
four experiments. Error bars represent S.E.M. B. Potency of the mTORC1 inhibitor everolimus, as determined by reduced phosphorylation of the
direct mTORC1 target p70 S6 kinase.
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difference in p70S6K phosphorylation between DEK-
NUP214 and control cells, analogous to its effect on
proliferation.
Discussion
This study is the first to demonstrate that the expression
of the fusion gene DEK-NUP214 leads to increased cel-
lular proliferation. We show that this is dependent on
upregulation of the signal transduction protein mTOR
with subsequent effects on protein synthesis and glucose
metabolism. We proceed to show that the proliferative
effect can be overcome by inhibition of mTORC1 with
everolimus, suggesting that patients with the DEK-NUP214
fusion gene may benefit from treatment with mTOR
inhibitors.
The biology of DEK-NUP214 is notoriously elusive.
Although the genetic translocation was characterized
almost two decades ago, only a few reports have studied
its role in leukemogenesis and none has been able to show
whether the contribution is on the level of proliferation or
differentiation. We find in this study that DEK-NUP214
increases the proliferation of myeloid cells. This is a
property shared by several fusion proteins, the most
similar being SET-NUP214, which contains the same
portion of NUP214 [23]. But also other nucleoporin fu-
sions such as NUP98-HOXA9 and NUP98-HHEX show
similar pro-proliferative properties both in culture and
in vivo [24-26]. In some aspects, this finding is in contrastwith a previous study of the NUP214 gene, which also
included one DEK-NUP214 clone. This clone displayed
equal or slightly lower proliferation as compared to
wild-type cells [8]. We cannot with certainty determine
the reason for this discrepancy but it may be the result of
different expression levels of the fusion gene. Interestingly,
Boer et al. selected the clone with the highest inducible
expression of DEK-NUP214 for their proliferation experi-
ment. As with some other oncogenes, DEK-NUP214 may
promote proliferation at low or moderate levels and
inhibit proliferation when highly expressed. Such a disad-
vantageous effect of high gene expression could also ex-
plain the low expression levels of DEK-NUP214 in cells
with stable expression of the gene; both our clones and cells
from patients with the t(6;9)(p23;q34) translocation [27].
In characterizing the proliferative effect, we find that
DEK-NUP214 promotes signaling through the mTOR
pathway. We demonstrate that DEK-NUP214 increases
the level of mTOR protein, without affecting any of
the upstream regulators AMPK, GSK3 or Akt. Despite
extensive characterization of mTOR activation, surpris-
ingly little is known about the regulation of its expression.
β-catenin is known to influence the transcription of mTOR
[28] but since this was unaffected by DEK-NUP214, we
suggest another mode of regulation. The mechanism
remains to be investigated and may involve miRNA-
mediated inhibition of translation, subcellular relocali-
zation or covalent modification, but most likely involves
the stabilization of mTOR by protein-protein interaction,
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such as Raptor [29], C/EBPδ [30], Tti1 [31] and Tel2 [31].
We also see an increase in the level of mTOR protein
phosphorylated on Ser2448. This phosphorylation is medi-
ated by p70S6K in a feedback loop, whose effect on the
activity of mTOR is not yet understood [32,33]. The
increase in mTOR-p-Ser2448 may arise from the observed
activation of p70S6K or may reflect the increased avail-
ability of mTOR protein in cells expressing DEK-NUP214.
By examining the phosphorylation of their substrates, we
can conclude that in this context, the increased level of
mTOR confers increased activity of mTORC1 but not
mTORC2. The reason for this may be that the availability
of the other factors of the complexes makes mTORC1
more susceptible to an mTOR increase or that the
mTORC1 substrates are more sensitive to changes in
mTOR complex activity.
To address the functional relevance of the increased
mTOR signaling, we analyzed the cellular translation
rate. The first day after seeding, nutrients and growth
factors are readily available and the conditions for trans-
lation are highly favorable. The rate of translation is
subsequently very high. Hence, it is not very surprising
that the expression of DEK-NUP214 does not markedly
enhance the translation rate at this time point. However,
three days after seeding, the control cells have decreased
their rate of protein synthesis by two thirds whereas the
cells expressing DEK-NUP214 sustain a 68% higher trans-
lation rate than the control cells. Due to the rapid growth
and proliferation of cancer cells, they require extensive
protein synthesis also when nutrients and growth factors
are scarce [34]. This key feature is crucial for malignant
transformation and could be a mechanism by which DEK-
NUP214 contributes to leukemogenesis.
A more recently discovered function of mTOR is in glu-
cose metabolism. Most cancer cells initially rely heavily on
aerobic glycolysis, a phenomenon known as the Warburg
effect [35]. However, as proliferation increases, so does the
energy demand. A second metabolic shift can serve to
reestablish the more energy-efficient oxidative phosphoryl-
ation, while also providing metabolites for macromolecule
anabolism [36]. Dysregulation of the mTOR pathway
has been proposed as such an event, as overactivation of
mTORC1 leads to a shift from glycolysis to oxidative
phosphorylation [15]. Our findings confirm this notion.
Cultures of cells expressing DEK-NUP214 produce less
lactate but consume as much glucose as cultures of control
cells, indicating such a shift. Given the higher proliferation
rate and thus higher number of cells in the DEK-NUP214
cultures, the glucose consumption per cell is somewhat
lower than for the control cells. However, this decrease
alone cannot explain the decrease in lactate levels, since a
reduction in glucose consumption that only offsets the
effect of increased proliferation on total glucose levelswould consequently also only offset the effect of prolifera-
tion on total lactate levels. What we observe here is a
reduction in total lactate levels, thus indicating a metabolic
shift from glycolysis to oxidative phosphorylation.
mTOR has attracted widespread attention as a target
for cancer therapy and several variants of the original
mTOR inhibitor rapamycin are being evaluated in clinical
trials, both for solid tumors and leukemias [18]. One of
these is everolimus, which employs the same mechanism
of action as rapamycin and has been approved by the FDA
for the treatment of renal cell carcinoma [17]. Our results
show that treatment with everolimus completely ablates
the proliferative phenotype induced by DEK-NUP214.
Strikingly, it does so at concentrations that do not affect
the control cells. This may be because the higher prolifer-
ation rate of the DEK-NUP214 cells produces higher
demands and thus increased dependence on mTORC1
signaling. Compensatory pathways may thus be able to
sustain the proliferation rate of the control cells but not
the increase caused by the expression of DEK-NUP214.
These results demonstrate that the increased proliferation
by DEK-NUP214 is indeed dependent on mTORC1.
Furthermore, it suggests that patients with leukemias
harboring the t(6;9)(p23;q34) may benefit from treatment
with the novel mTOR inhibitors that are becoming increas-
ingly available.
Conclusions
The DEK-NUP214 fusion gene is associated with poor
prognosis in acute myeloid leukemia but its contribution
to the disease remains largely unknown. In this study, we
expressed DEK-NUP214 in the AML cell line U937 and
show that this leads to increased expression of mTOR as
well as increased phosphorylation of the mTORC1
substrate p70S6K but not the mTORC2 substrate Akt.
Consistent with increased mTORC1 activation, the cells
also display increased protein translation and a metabolic
shift from glycolysis to oxidative phosphorylation. Cells
expressing DEK-NUP214 also proliferate faster, a differ-
ence that is abrogated by treatment with the mTORC1
inhibitor everolimus at a concentration that does not
affect the proliferation or the viability of the control cells.
This demonstrates that the proliferative effect is dependent
on mTOR and suggests that cells carrying the DEK-
NUP214 fusion gene may be sensitive to treatment with
the mTOR inhibitors currently being evaluated for the
treatment of leukemia.
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